SENS Jan 2025 3.000 put
| Previous close | 1.9700 |
| Open | 1.9700 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 3.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.9700 - 2.1900 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
Business WireSenseonics to Participate in the Jefferies Healthcare Conference
GERMANTOWN, Md., May 26, 2023--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Jefferies Healthcare Conference in New York, NY.
ZacksSenseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates
Senseonics (SENS) delivered earnings and revenue surprises of 0% and 35.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireSenseonics Holdings, Inc. Reports First Quarter 2023 Financial Results
GERMANTOWN, Md., May 09, 2023--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended March 31, 2023.
Business WireSenseonics Holdings, Inc. Schedules First Quarter 2023 Earnings Release and Conference Call for May 9, 2023, at 4:30 p.m. Eastern Time
GERMANTOWN, Md., April 27, 2023--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2023 financial results after market close on Tuesday, May 9, 2023.
Business WireSenseonics Announces the First Pediatric Study Participant Insertions in the ENHANCE Clinical Trial
GERMANTOWN, Md., April 18, 2023--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the first pediatric study participant has been inserted with Eversense® 365-day system as part of the pivotal ENHANCE clinical trial at the AMCR Institute, a clinical research center focused on pre-diabetes, type 1, type 2 diabetes
Business WireSenseonics Announces Equity Grants To Employees Under Inducement Plan
GERMANTOWN, Md., April 05, 2023--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it had made equity grants to new employees under its 2019 Inducement Plan (the "Plan") in accordance with NYSE American Company Guide Section 711(a).
Business WireSenseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
GERMANTOWN, Md., March 15, 2023--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended December 31, 2022.
ZacksSol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates
Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -92.31% and 94.60%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Health Catalyst (HCAT) Reports Q4 Loss, Tops Revenue Estimates
Health Catalyst (HCAT) delivered earnings and revenue surprises of 50% and 1.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksPulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 7.32% and 11.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireSenseonics Holdings, Inc. and PHC Holdings Corporation To Host Joint Eversense CGM Virtual Analyst and Investor Event on March 15, 2023
GERMANTOWN, Md., February 17, 2023--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to host a joint virtual analyst and investor event alongside PHC Holdings Corporation, the parent company of Senseonics’ global commercial partner, Ascensia Diabetes Care, on Wednesday, March 15, 2023 at 6:30pm ET.
ZacksComputer Programs and Systems (CPSI) Beats Q4 Earnings and Revenue Estimates
Computer Programs and Systems (CPSI) delivered earnings and revenue surprises of 3.39% and 2.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireSenseonics to Present at the Stifel 2022 Healthcare Conference
GERMANTOWN, Md., November 09, 2022--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel Healthcare Conference in New York, NY.
Business WireSenseonics Holdings, Inc. Reports Third Quarter 2022 Financial Results
GERMANTOWN, Md., November 08, 2022--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended September 30, 2022.
Business WireSenseonics and Ascensia Announce a Collaboration with the Nurse Practitioner Group Designed to Expand Patient Access by Providing In-Office and At-Home Insertion Options for Eversense® E3 Continuous Glucose Monitoring System (CGM)
GERMANTOWN, Md., November 03, 2022--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, and Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® blood glucose monitoring (BGM) system portfolio and exclusive distributor of Eversense® CGM Systems, today announced the launch of a collaboration with the Nurse Pr
Business WireSenseonics Holdings, Inc. Schedules Third Quarter 2022 Earnings Release and Conference Call for November 8, 2022, at 4:30 p.m. Eastern Time
GERMANTOWN, Md., October 25, 2022--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2022 financial results after market close on Tuesday, November 8, 2022.
ZacksSelect Medical (SEM) Plans 3rd Hospital in Central Pennsylvania
Select Medical (SEM) joins forces with UPMC to open its third inpatient rehabilitation hospital in Central Pennsylvania to better address the region's post-acute care needs.
- Zacks
Encompass Health (EHC) Plans Hospital to Aid Florida Footprint
Encompass Health (EHC) unveils plans to fortify its U.S. presence via building a 50-bed inpatient rehabilitation hospital in The Villages, Florida.
ZacksCigna's (CI) Arm Adds Five Digital Health Apps to Its Platform
Cigna's (CI) unit bolsters its clinical platform Digital Health Formulary by including five on-line solutions, aiming to relieve people from chronic medical conditions.
Business WireSenseonics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
GERMANTOWN, Md., September 07, 2022--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.
ZacksHumana (HUM) Brings Home Health Unit of KAH Under CenterWell
Humana (HUM) wraps up rebranding KAH's home health operations to the CenterWell brand. This leads to the clubbing of HUM's three payer-agnostic care services into a common suite.
Business WireSenseonics Announces CFO Transition
GERMANTOWN, Md., September 01, 2022--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced its Chief Financial Officer, Nick Tressler, is transitioning from his position, effective September 1, 2022. Rick Sullivan, Senseonics' current Vice President of Finance, has been appointed to succeed Mr. Tressler as Chief Finan
Business WireSenseonics to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
GERMANTOWN, Md., August 17, 2022--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to present at the upcoming Inaugural Gilmartin Group Emerging Showcase, taking place virtually. Management is scheduled to present on Wednesday, August 31, 2022 at 3:00pm ET.
ZacksSenseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates
Senseonics (SENS) delivered earnings and revenue surprises of 25% and 12.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireSenseonics Holdings, Inc. Reports Second Quarter 2022 Financial Results
GERMANTOWN, Md., August 09, 2022--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended June 30, 2022.